HER2+ status is associated with aggressive disease1
HER2 positivity is correlated with decreased survival1
These patients did not receive HER2-directed therapy.
Breast carcinoma tissue from primary breast cancer biopsies was obtained from randomly selected patients (n=220) treated at the Glasgow Royal Infirmary between 1984 and 1993. Overall survival was decreased for patients with tumors that were intensely stained (HER2+) by immunohistochemistry (risk ratio=1.18; P<0.0001) compared with patients who tested negative for HER2.1
P value represents log-rank difference in cumulative survival. HER2 was localized using the ICR12 antibody. Survival curve for patients with HER2+ (IHC 3+; n=50) vs HER2-negative (IHC 0 or 1+; n=85) disease.
Patients with breast tumors that over-express HER2 have shorter time to relapse and reduced overall survival2-6
HER2 positivity is a negative prognostic factor that should be considered even in patients conventionally considered low risk for disease recurrence1,7
- Patients with HER2+ disease with small tumors8
- Patients with HER2+ and hormone receptor + disease9